Sierra Oncology, Inc. (SRRA) financial statements (2022 and earlier)

Company profile

Business Address 1820 GATEWAY DRIVE
SAN MATEO, CA 94404
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments105104148106100109150
Cash and cash equivalents105104148106100109150
Receivables000100 
Prepaid expense1111010
Other current assets1100000
Other undisclosed current assets1011111
Total current assets:107106150109102110152
Noncurrent Assets
Operating lease, right-of-use asset101
Property, plant and equipment0000001
Other noncurrent assets1111000
Total noncurrent assets:2111011
TOTAL ASSETS:109107151109102111153
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities107510787
Accounts payable2211130
Accrued liabilities1119657
Employee-related liabilities743    
Debt  0    
Derivative instruments and hedges, liabilities  46    
Other liabilities      0
Other undisclosed current liabilities3213    
Total current liabilities:1396510787
Noncurrent Liabilities
Long-term debt and lease obligation0005   
Long-term debt, excluding current maturities   5   
Operating lease, liability000
Other undisclosed noncurrent liabilities(0)(0)     
Total noncurrent liabilities:0005   
Total liabilities:13106515787
Stockholders' equity
Stockholders' equity attributable to parent9698869495103145
Preferred stock  0    
Common stock0000000
Additional paid in capital1,037945852772719685680
Accumulated deficit(941)(847)(766)(677)(624)(582)(534)
Total stockholders' equity:9698869495103145
TOTAL LIABILITIES AND EQUITY:109107151109102111153

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 0     
Gross profit: 0     
Operating expenses(95)(65)(67)(55)(43)(48)(36)
Operating loss:(95)(65)(67)(55)(43)(48)(36)
Nonoperating income (expense)(0)(16)(21)210(17)
Other nonoperating income (expense)(0)0(1)2100
Loss from continuing operations before income taxes:(95)(81)(88)(54)(42)(48)(53)
Income tax expense (benefit)0(0)00(0)(0)(0)
Net loss attributable to parent:(95)(81)(88)(53)(42)(48)(53)
Preferred stock dividends and other adjustments      (374)
Other undisclosed net loss available to common stockholders, basic      (26)
Net loss available to common stockholders, diluted:(95)(81)(88)(53)(42)(48)(453)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(95)(81)(88)(53)(42)(48)(53)
Comprehensive loss, net of tax, attributable to parent:(95)(81)(88)(53)(42)(48)(53)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: